Novel anti-amyloid-beta (A β) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review

CONCLUSIONS: Lecanemab therapy led to a substantial decrease in amyloid plaques and a noticeable slowing of clinical decline. The findings suggest a meaningful connection between the reduction in amyloid and the positive impact on patients' clinical outcomes, hinting at potential disease-modifying effects.PMID:37902139 | PMC:PMC10617290 | DOI:10.1177/03946320231209839

Source: International Journal of Immunopathology and Pharmacology - October 30, 2023 Category: Allergy & Immunology Authors: Selia Chowdhury Nurjahan Shipa Chowdhury Source Type: research